|
| Press Releases |
|
 |
|
| Wednesday, September 8, 2021 |
|
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药，一家专注于肿瘤治疗领域的创新型全球生物制药公司，今日宣布其口服泛PI3K抑制剂buparlisib（AN2025）、口服EP4拮抗剂（AN0025）与PD-L1抑制剂atezolizumab（阿替利珠单抗）三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。
more info >> |
|
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
| 阿諾醫藥，一家專注於腫瘤治療領域的創新型全球生物製藥公司，今日宣佈其口服泛PI3K抑制劑buparlisib（AN2025）、口服EP4拮抗劑（AN0025）與PD-L1抑制劑atezolizumab（阿替利珠單抗）三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
| Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
| Thursday, July 15, 2021 |
|
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
| Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
ポスト不況時代の日本において、「人単合一モデル」が持つ戦略的意義
Jan 23, 2022 19:00: JST
|
|
|
Pixis (Formerly Pyxis One) Raises $100M in SoftBank Vision Fund 2-led Series C to Grow Its Codeless AI Infrastructure
Jan 22, 2022 02:00: JST
|
|
|
Pixis (Formerly Pyxis One) Raises $100M in SoftBank Vision Fund 2-led Series C to Grow Its Codeless AI Infrastructure
Jan 22, 2022 02:00 HKT/SGT
|
|
|
2022's First SPAC and Metaverse Investment Opportunities Virtual Investment Conference in Hong Kong
Jan 21, 2022 20:50: JST
|
|
|
由达博思、新盛控股及Mileage Singapore共同举办2022年香港首个SPAC及元宇宙在线投资论坛
Jan 21, 2022 19:37 HKT/SGT
|
|
|
由達博思、新盛控股及Mileage Singapore共同舉辦2022年香港首個SPAC及元宇宙線上投資論壇
Jan 21, 2022 19:36 HKT/SGT
|
|
|
2022's First SPAC and Metaverse Investment Opportunities Virtual Investment Conference in Hong Kong
Jan 21, 2022 19:35 HKT/SGT
|
|
|
Yeahka ranks No. 1 in the non-bank independent QR code payment service market in China
Jan 21, 2022 17:51 HKT/SGT
|
|
|
深耕“AI+”高成长赛道 创新奇智营收数据亮眼发展持续向好
Jan 21, 2022 17:35 HKT/SGT
|
|
|
深耕「AI+」高成長賽道 創新奇智營收數據亮眼發展持續向好
Jan 21, 2022 17:34 HKT/SGT
|
|
|
创新奇智香港招股进行中 奋力冲刺“AI+制造”第一股
Jan 21, 2022 17:27 HKT/SGT
|
|
|
創新奇智香港招股進行中 奮力衝刺「AI+製造」第一股
Jan 21, 2022 17:26 HKT/SGT
|
|
|
Pixis（旧Pyxis One）、コードレスAI基盤の成長を目指し、SoftBank Vision Fund 2が主導するシリーズC資金1億ドルを確保
Jan 21, 2022 16:00: JST
|
|
|
Pixis（旧Pyxis One）、コードレスAI基盤の成長を目指し、SoftBank Vision Fund 2が主導するシリーズC資金1億ドルを確保
Jan 21, 2022 16:00: JST
|
|
|
国际天食集团有限公司宣布改名「上海小南国」
Jan 21, 2022 15:59 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
